Since PHA-739358 and R763/AS703569 are active against Aurora kinases as well as BCR-ABL [84], [85], [100]–[102], we intended to dissect the significance of aurora kinase versus BCR-ABL inhibition for anti-proliferative and pro-apoptotic activity of AKIs in BCR-ABL transformed cells harboring known BCR-ABL resistance mutations as well as mutations in Aurora B. It has already been shown, that AKIs like VX-680 are active in patients with BCR-ABL T315I leukemia [103], [104]. This evidence concerns the gene ABL1 and leukemia.